07–09 December | Klinikum rechts der Isar | Munich | Germany
Programme 2017 2017-12-11T12:15:32+00:00

Faculty

Register now

Newsletter

Programme 2017

DOWNLOAD PROGRAMME
PROGRAMME OVERVIEW

Thursday, December 7

* Competing for the MAC Award

TimeNameDescription

09.00-10.00

CAR 1: Asymptomatic carotid disease – how to select reliably individuals with an increased carotid-related stroke risk
Chair: Hans-Henning Eckstein, Holger Poppert

Alison HallidayA simple long-term stroke risk model for asymptomatic carotid stenosis – will it help us select patients for intervention in the future?
Daniel StaubMorphological duplex ultrasound criteria - how to assess and report echolucency, inhomogeneity and ulceration
Henrik SillesenPlaque area and plaque volume rather than the degree of stenosis are suitable predictors for an increased stroke risk
Andreas Schindler*The risk of MR-detected carotid plaque hemorrhage on recurrent or first-time stroke: a meta-analysis of individual participant data
Peter RinglebKeynote Lecture: Are Transcranial Doppler (TCD) embolization, impaired cerebrovascular reserve, stenosis progression and silent infarctions suitable tools to select patients for CEA or CAS?

10.00-11.00

CAR 2: Update on carotid trials and guidelines
Chair: Henrik Sillesen, Werner Hacke

Gert de BorstThe most important recommendations from the 2017 ESVS/ESC guideline on the management of carotid artery disease
Mandy Müller*The procedural risk of carotid revascularisation declined over time – data from the Carotid Stenosis Trialists Collaboration
Andreas Kühnl, Sofie SchmidThe impact of age and sex on stroke and death rates after CEA or CAS – data from the German Carotid Registry
Leo BonatiRestenosis and its impact on recurrent stroke risks after CAS and CEA for symptomatic carotid stenosis – results from the International Carotid Stenting Study
Richard BulbuliaAsymptomatic Carotid Endarterectomy Risk Score (ACER score): An individual patient data meta-analysis to identify risk factors for procedural stroke among 6,500 patients undergoing CEA in the VACS, ACAS, ACST-1 and GALA RCTs
Christoph KnappichIntraoperative morphological control after CEA - angiography or duplex ultrasound, first results from the CIDAC (Comparison of Intraoperative Duplex Ultrasound and Angiography after Carotid Endarterectomy) trial

11.30-12.40

CAR 3: Emergency treatment of ischemic strokes
Chair: Claus Zimmer, Martin Dichgans

Werner HackeKeynote Lecture: Mechanical thrombectomy: which results can we expect in clinical routine? Exit light - enter night
Holger PoppertHow to optimize the logistics of endovascular stroke treatment - should the patient come to the doctor or vice versa?
Laura CapocciaUrgent/emergency CEA in stroke patients
Moritz WildgruberCarotid-related strokes with intracranial embolism –endovascular treatment with simultaneous or staged CAS (or CEA)
Klaus MathiasAcute carotid artery occlusion – why endovascular intervention is the therapy of first choice

12.45-13.00

Christos Liapis

Special lecture: Vascular surgery in the wake of financial crisis

14.00-15.10

CAR 4/ PAD 1: Deciphering molecular and cellular mechanisms of atherosclerotic plaque destabilization
Chair: Lars Maegdefessel, Gert de Borst

Claudia MonacoKeynote lecture: Targeting inflammatory processes in atherosclerosis
Sumaira MacdonaldRationale for statin use in carotid intervention - periprocedural and long-term effects on plaque stability
Ljubica Perisic MaticNovel markers and mechanisms of plaque rupture governed by smooth muscle cells
Hendrik SagerAcute and chronic stress as triggers of plaque vulnerability
Leonie Fassaert*Preoperative hypertension is associated with atherosclerotic plaque vulnerability in patients undergoing carotid endarterectomy

15.40-16.35

CAR 5: Carotid plaque erosion, plaque vulnerability and perspectives in functional imaging
Chair: Peter Ringleb, Eva Bartels

Philipp Nicol, Michael Joner
Novel insights into atherosclerosis: from pathology to invasive imaging
Daniel StaubUse of contrast-enhanced ultrasound for risk stratification of carotid plaques
Martin DichgansThe carotid plaque imaging in acute stroke (CAPIAS) study and the potential role of ipsilateral complicated AHA lesion type VI carotid artery plaques in patients with cryptogenic stroke
Angelos Karlas, Vasilis Ntziachristos, Michael KallmayerRecent advances in the diagnostics of carotid lesions by MultiSpectral Optoacoustic Tomography (MSOT)

16.55-18.10

CAR 6: Carotid artery stenting (CAS) - out on the track again?
Chair: Leo Bonati, Michael Kallmayer

Gert de BorstEvidence for periprocedural antiplatelet therapy in carotid artery stenting
Ralf KolvenbachTranscervical carotid stenting (T-CAR ) with flow reversal versus CEA under regional anesthesia in symptomatic patients – a comparative DWI controlled trial
Michel BosiersCLEAR-ROAD: a physician-initiated study investigating the RoadSaver stent in carotid lesions.
Sumaira MacdonaldRationale for the use of regional or local anesthetic rather than general anesthetic during transcarotid artery stenting (T-CAR)
Evelien de Vries*The effect of stent design on clinical and radiological outcome of CAS: a systematic review and meta-analysis
Richard BulbuliaChoices of stent and cerebral protection in the ongoing ACST-2 Trial
Laura CapocciaPlaque Prolapse Prevention in CAS (3PCAS) – a RCT assessing Subclinical Brain Lesions by DWI after CAS with closed-cell stents and mesh-covered stents

* Competing for the MAC Award

TimeNameDescription

10.30-12.40

AOR 1: Short communications I - Aortic diseases
Chair: Stefan Ockert, Marc Bailey, Jürgen Falkensammer, Igor Končar

Clark ZeebregtsThe potential benign nature of type Ia endoleaks after fenestrated Anaconda EVAR – truth or myth?
Jean Paul de VriesMid-term results of 300+ patients treated by endovascular aortic sealing (EVAS)
Ralf KolvenbachHow much open surgery is still required for the treatment of AAAs?
Tony Soares*Direct oral anticoagulants in the treatment of mural thrombus in near-normal aortic wall
Amr Abdel Rahim*Retrograde mesenteric bypass case report
Andriy Nykonenko*Visceral branches aneurym of the abdominal aorta: anatomical layout and choice of treatment
Mikhail Generalov*Endovascular management of isolated iliac artery aneurysms - single-center experience
Didem Melis Oztas*Cerebral protection during aortic de-branching with temporary cross-over bypass between external carotid arteries followed by TEVAR – mid-term results
Patrick Nierlich*Atypical debranching in patients undergoing TEVAR for thoracoabdominal aortic aneurysm type II
Mario LescanEarly experiences with the Relay Double Branch graft
Alice Cabral Lopes*Endovascular treatment of hepatic artery pseudoaneurysm after pancreticoduodenectomy
Iryna Shevchenko*Surgical treatment of the aneurysm of the abdominal aorta after an unsuccessful endovascular treatment in the presence of its quick growth and a nonspecific gastrointestinal bleeding
Florian Simon*Preoperative pharmacological conditioning affects the clinical and molecular outcome of ischemia / reperfusion injury of the spinal cord after thoracic aortic clamping - a mouse model
Wolf Eilenberg*Novel screening tool for abdominal aortic aneurysms based on Plasma D-Dimer and Myeloperoxidase
Mohammed A Waduud*Management of ruptured abdominal aortic aneurysms (rAAA): 10-year experience at a tertiary referral centre in Northern England
Rolf WeidenhagenEmergency treatment of ruptured AAA after EVAR (rEVAR)
Christian ReepsManagement of Blunt Thoracic Aortic Injury – how volume affects the outcomes
Albert BuschA novel preclinical experimental model of AAA disease using genetically mutated LDLR-/- mini-pigs
Anna MengesThe weakening of the aortic wall in type II endoleaks – an immuno-histochemical and molecular analysis
Sarah GeisbüschTemporal trends of hospital incidence, treatment, and in-hospital mortality following open and endovascular surgery for thoracic aortic aneurysms in Germany from 2005 to 2014: secondary data analysis of the nationwide German DRG microdata
Benedikt ReutersbergIncidence and Outcome of surgically treated patients with aortic dissections - Secondary data analysis of the nationwide German DRG statistics from 2006 to 2014
Qasam Ghulam*Thrombus volume and thickness in AAA by 3D-CEUS

14.00-15.00

AOR 2: Endovascular aortic arch repair - how far can we go?
Chair: Christoph Nienaber, Alexander Zimmermann

Nick CheshireEndo versus open arch repair - what is evidence - what is anecdote?
Martin CzernyTotal endovascular aortic arch repair in patients who cannot undergo classical surgery - the double endo approach
Ralf KolvenbachThe role of stent grafts in ascending aortic aneurysms
Stephan HaulonAdvances and perspectives of arch endografts
Tilo KölbelHow to protect the brain during aortic arch endografting?
Richard GibbsHow to prevent cerebral (micro)embolism during TEVAR of the aortic arch

15.30-17.00

AOR 3: Acute aortic dissections – lessons from the International Registry of Aortic Dissections (IRAD) and other trials
Chair: Jan Brunkwall, Bijan Modarai, Richard Gibbs

Santi TrimarchiKeynote lecture: Rationale, design and key findings from the International Registry of Acute Aortic Dissection (IRAD)
Christoph NienaberThe ongoing discussion about the definition of “complicated” and “uncomplicated” type B aortic dissections – current status
Foeke NautaEarly outcomes of acute retrograde dissection in the aortic arch and the ascending aorta – data from IRAD
Natzi SakalihasanBiomarkers and functional imaging in acute aortic dissections – the LIege study on Dissected Aorta (LIDIA)
Martin CzernyEndovascular treatment of acute type A aortic dissections - the endo Bentall approach
Igor KončarEndovascular treatment of aortic dissection - role of debranching procedures
Friedhelm BeyersdorfWill we still need open surgery for acute aortic dissections in 2025? – a cardiovascular surgeon’s perspective

17.00-18.10

PAD 2: Short communications II: Peripheral Arterial Diseases (PAD)
Chair: Athanasios Giannoukas, Mihai Ionac, Sigrid Nikol

Aarent R.T. Brand*Pharmacology for peripheral arterial disease in the Netherlands; patient journey and platelet aggregation inhibitor prescription
Florian Enzmann*Tibio-distal vein bypass in critical limb ischemia and its role as a bail-out procedure for failed tibial angioplasty
Sigrid NikolA phase III randomized double-blind placebo-controlled study to assess placental PLX-PAD cells in CLI patients that are not eligible for revascularization
Vakhtang Kipiani*Endovascular treatment of TASC II C and D Lesions using different strategies
Diego Ruiz Chiriboga*Late groin complications after cardiac transplantation, repaired by endovascular techniques with unexpected findings in the wound
Mikhail Generalov*The use of bioactive stent heliflex in patients with atherosclerotic lesions of superficial femoral artery: The beginning of the study
Bernard Leenstra*The role of transcutaneous oxygen tension measurement in the assessment and classification of lower limb ischemia
Ivan Pertsov*Hyperhomocysteinemia as a marker of cardiovascular disease
Alexandr Korotkikh*Long-term results of cava filter implantation in the common iliac vein
Alexander ZimmermannClinical use and safety of the Lutonix DCB for the treatment of below-the-knee arteries: interim data from a prospective registry
Yvonne BausbackEndovascular femoro-popliteal bypass grafting via the femoral vein (PQ Bypass) - the DETOUR I study
Ulf TeichgräberThe effectiveness of the paclitaxel-coated Luminor® balloon catheter versus POBA in superficial femoral and popliteal arteries in preventing vessel restenosis or reocclusion: primary endpoint and 6 months results of a randomized controlled trial
TimeNameDescription

17.00-18.10

Mini-Symposium I: Aortic infections
Chair: Christian Reeps, Martin Björck

Hubert SchelzigInflammatory AAA and postoperative outcomes after open-surgery: a 10-year single-center experience and state of the art
Anders WanhainenEndoVAC hybrid treatment of vascular infection
Colin BicknellThe contemporary management of infected aortic grafts: endovascular stenting saves lives but definitive surgery is necessary
Martin CzernyTreatment of graft infections after open and endovascular aortic treatment by orthotropic reconstruction with bovine neopericardium from the root to the bifurcation
Thomas WyssThe European multicenter registry on pericardial grafts for aortic infections
Gabor BiroHow to design tube and bifurcated pericardial grafts (technical note)
Christian ReepsDeep vein remains to be a valid alternative for orthotope aortic repair

Friday, December 8

* Competing for the MAC Award

TimeNameDescription

08.30-09.30

AOR 4: Cutting-edge imaging technologies for the aorta
Chair: Nick Cheshire, Natzi Sakalihasan

Athanasios KatsargyrisUse of Fusion imaging in fenestrated and branched EVAR - does it work?
Jonathan NadjiriPerspectives of Magnetic Resonance Imaging (MRI) for aortic aneurysms and dissections
Michael RasperWhat Spectral CT Angiography could add in the (follow-up) diagnostics of aortic diseases
Jean Paul de VriesApposition software to calculate apposition of endografts in the aortic neck – prediction of EVAR failures during follow-up
Marc BaileyMolecular imaging of cell proliferation in pre-clinical abdominal aortic aneurysm

09.30-10.45

AOR 5: Novel concepts and insights from translational aortic aneurysm research
Chair: Philip Tsao, Lars Maegdefessel

Ronald DalmanKeynote Lecture: Pathophysiological impact of diabetes on AAA disease
Per ErikssonMolecular and cellular mechanisms of thoracic aortic aneurysms
Natzi SakalihasanCancer and AAA: a causal role for chronic inflammation?
Martin BjörckPhysical activity and the risk to develop AAA
Anders WanhainenTicagrelor and the inhibition of growth in small AAAs – results from a RCT
Clark ZeebregtsSkin accumulation of advanced glycation endproducts is increased in AAA patients

11.10-12.30

AOR 6: Chronic aortic dissections and thoraco-abdominal aortic aneurysms – technical issues and long-term outcomes
Chair: Tina Cohnert, Piotr Kasprzak, Friedhelm Beyersdorf

Clark ZeebregtsPerioperative mortality, paraplegia, stroke and long-term stent related complications after TEVAR for traumatic thoracic aortic lesions
Anders WanhainenA dissection-specific stent graft to prevent distal Stent-graft induced New Entry (dSINE)
Martin CzernyMechanisms of and treatment strategies for dSINE after TEVAR for acute and chronic type B aortic dissection- Insights from EuREC
Tilo KölbelFalse lumen embolisation: devices and techniques
Nabil ChakféAre all thoracic endografts the same?
Colin BicknellThe compliance with “best” medical therapy in type B aortic dissection patients is poor – we need to optimize medical treatments to improve long-term outcomes
Athanasios KatsargyrisUpdate on long-term durability of fenestrated and branched endografts for Thoraco-Abdominal Aortic Aneurysms (TAAA)

13.30-15.10

AOR 7: Abdominal aortic aneurysms (AAA) – genetics, guidelines and outcomes after open and endovascular repair
Chair: Anders Wanhainen, Jes Lindholt

Philip TsaoKeynote lecture: Genetics of AAA – what clinicians need to know in 2017
Ron DalmanUpdate on the 2017 AAA management guidelines of the Society of Vascular Surgery (SVS)
Frank VermassenThe 5.5 cm/5 cm threshold is completely arbitrary, some AAAs rupture at smaller diameters
Bijan ModaraiDeterminants of survival after EVAR - an analysis of >700 endovascular aortic procedures to determine 5-year survival
Ian LoftusEVAR and open repair show equivalent outcomes in younger patients - predicting long-term outcomes
Thomas Schmitz-RixenA real-world based score to assess the procedural risk of EVAR and OR for non-ruptured AAA – data from the aortic registry of the German Vascular Society (DGG)
Athanasios GiannoukasMid- and long-term renal function outcomes after elective EVAR vs. OR: do we really know enough on which treatment is superior
Hubert SchelzigCentralising therapy of non-ruptured and ruptured AAA – update of the facts

15.40-16.40

AOR 8: Endoleaks type I and III – still an unresolved issue in endovascular repair of juxtarenal AAA and TAAA
chair: Ron Dalman, Hubert Schelzig

Stephan HaulonHow I plan and perform fenestrated aortic endografting and how I flare the viscero-renal grafts to prevent type III endoleaks
Ralf KolvenbachRoutine closure of gutters with liquid polymer solves the chimney problem and makes them as good as fenestrated grafts
Afshin AssadianViscero-renal stentgraft for chimneys, FEVAR and BEVAR – which one is better or are they all the same?
Pjotr KasprzakPatient selection in hostile necks and how to prevent endoleaks – a word of caution
Ian LoftusThe role of parallel grafts and endovascular aortic sealing (EVAS) - do they fill a gap?
Jürgen FalkensammerBenchside testing for patient safety: assessment of pull-out forces before complex EVAR

16.10-17.55

CAR 7/PAD 8/AOR 9: Radiation protection and team training 2017
Chair: Moritz Wildgruber, NN

Bijan ModaraiKeynote lecture: Determinants of occupational radiation exposure and current practice of radiation protection in the Hybrid OR
Houman JalaieRadiation exposure during venous stenting
Klaus MathiasKey points in radiation protection in the angio lab – experiences and advices from an endovascular pioneer
Heiko WendorffITIX: Influence of an intensive radiation-protection-Training on the Intraoperative X-ray-radiation exposure in a hybrid OR
Jan BrunkwallIs the Vessel Navigator of any benefit for the patient? - results from a comparison of (T)EVAR with and without
Tina CohnertHybrid OR with an installed „Zero Gravity“ radiation protection system
Lars LönnAssessment of competence in EVAR procedures – A novel rating scale using Delphi technique
Colin BicknellGeneration of high performance teams in emergency aortic surgery: Simulated leadership and team training is effective in improving the outcomes and safety of procedures
Johannes GahlenHow to build up and train an endovascular team of doctors, nurses and technicians – a particular challenge for Hybrid ORs

16.45-18.15

CAR 8: Short communications III: Carotid stenosis (CAR)
Chair: Richard Bulbulia, Kornelia Kreiser, Daniel Staub

Alexandr Korotkikh*Carotid endarterectomy and carotid stenting in patients with atrial fibrillation with using Dabigatran Etexilate
Peter Konstantiniuk*Smoking is a significant risk-factor for postoperative cerebral events in CABG and simultaneous internal carotid endarterectomy
Amedeo Carmignani*Clinical and cytological correlation in the vulnerable atherosclerostic carotid plaque: monocentric experience
Grigorios Voulalas*Smooth muscle cells‘ level of MMP-9 and TIMP-1 could potentially indicate plaque instability
Iryna Shevchenko*Case of successful combined treatment of giant paraganglioma of neck
Didem Melis Oztas*How to clamp and revascularize the brain if the patient has only single vessel blood supply that contains severe stenosis?
Armelle Meershoek*CEA for patients with a recurrent symptomatic internal carotid artery near occlusion with full collapse: report of 17 cases
Ian David van Koeverden*Repeated carotid endarterectomy: Do plaques change over time?
Konstantinos Spanos*A long-term observational study of carotid artery treatment
Alexander ZimmermannPerioperative platelet inhibition is a MUST - data from the German Carotid Registry on 117,973 procedures
Michael KallmayerTranscarotid Artery Stenting (T-CAR) with flow reversal – our experience with this innovative tool to treat carotid stenoses
Vanessa Pourier*Innervation of extracranial carotid aneurysms and popliteal aneurysms
Christoph SchäfferThe assessment of carotid stenoses by contrast-enhanced tomographic ultrasound
Andreas KühnlSignificant association between the neurological status on admission and the in-hospital risk of stroke or death after CEA and CAS

* Competing for the MAC Award

TimeNameDescription

08.30-09.30

PAD 3: Randomized Controlled Trials (RCT) on Critical Limb Ischemia (CLI) and Intermittent Claudication
Chair: Frank Vermassen, Thomas Zeller

Jean Paul de Vries1-year results of the RAPID trial – a RCT between Legflow DCB and Supera stent versus Supera stent only
Yvonne Bausback, Dierk Scheinert 2-year result of the REAL PTX randomized trial comparing Silver PTX versus DCB in femoro-popliteal lesions
Gunnar Tepe Drug-coated balloons versus uncoated PTA balloons for femoro-popliteal lesions – 12-month results from the randomized RANGER trial
Yvonne Bausback, Dierk Scheinert Compare I: Pilot Study to compare the Ranger DCB with IN.PACT DCB in patients with femoro-popliteal artery disease
Gabor Biro, Alexander Zimmermann, Mark BosiersFirst results from the ZILVERPASS Study: a RCT comparing ZILVER PTX stenting with bypass surgery in femoro-popliteal lesions
Florian Enzmann*Stent versus bypass for femoro-popliteal TASC II Type C and D lesions: preliminary data of a prospective randomized trial
Thomas ZellerEndovascular atherectomy versus open femoral endarterectomy – rationale and design of the randomized PESTO Trial

09.30-10.35

PAD 4: Update on atherectomy and drug-eluting technologies
Chair: Klaus Overbeck, Heiko Wendorff


Richard GibbsOpen surgery or stenting for aortoiliac occlusive disease - which is best?
Reza GhotbiTechnique and outcomes of Laser-Atherectomy for calcified femoro-popliteal lesions
Frank VermassenUpdate on drug-eluting balloons (DEB) – are they all the same?
Michel BosiersBIOLUX 4EVER and IN.PACT Flexion: physician-initiated studies on DCB and bare metal stents in femoro-popliteal and popliteal lesions
Gunnar TepeUnmet need in SFA treatment: severe calcium - what the „shockwave (lithotrypsy)“ device might add (data of the PAD II study)
Thomas ZellerKeynote Lecture: Technological perspectives for endovascular therapy of the lower limb

11.00-12.15

PAD 5: PAD - a marker disease for atherosclerosis – update on antithrombotic and lipid-lowering therapy
Chair: Heribert Schunkert, Christos Liapis

Jes LindholtKeynote lecture: Population screening and intervention for vascular disease in Danish men (VIVA): a randomized controlled trial
Christine Espinola-KleinThe secondary prevention of major cardiovascular events in patients with CHD or PAD - What can we learn from EUCLID and COMPASS, evaluating Clopidogrel, Ticagrelor and Rivaroxaban
Thomas StadlbauerIs the combination of antithrombotics and low-dose anticoagulants worthwhile in PAD – the VOYAGER trial
Richard BulbuliaCholesterol: The good, the bad and the ugly! Results of recent HDL-C raising trials to prevent vascular disease
Heribert Schunkert The impact of Evolocumab (PCSK 9i) on clinical outcomes in patients with cardiovascular disease – the randomized FOURIER study
Christine Espinola-KleinKey recommendations on antithrombotic and lipid-lowering therapy from the 2017 guidelines of the European Society for Cardiology

12.15-12.30

Mihai Ionac

Special lecture: The “vasculo-plastic” approach to reduce the number of lower limb amputations due to chronic tissue loss

13.30-14.45

PAD 6: New assessment tools for Critical Limb Ischemia (CLI)
Chair: NN, Ulf Teichgräber

Frank VermassenAngiosomes - a failed concept?
Bijan ModaraiNovel assessment of haemodynamics (pressure, flow, fractional flow reserve) in the peripheral vasculature using the Combowire
Jean Paul de VriesDETECT-PAD - a computerized model to predict the pressure drop in borderline iliac artery stenosis on the basis of MRA
Lars LönnLesions in the superficial femoral artery (SFA) characterized with velocity ratios using vector velocity ultrasound
Klaus OverbeckEndovascular treatment of aorto-iliac TASC D occlusions with fusion imaging, outback catheters, dedicated wires and stent grafts
Achim NeufangArm veins are a reliable and durable graft material in femoro-popliteal and distal bypass surgery

14.45-15.40

PAD 7: Acute Limb Ischemia (ALI) - open or endovascular treatment?
Chair: Thomas Schmitz-Rixen, Markus Steinbauer

Michel BosiersThe ROBINSON study: a physician-initiated study investigating the Rotarex Catheter in femoro-popliteal in-stent occlusions
Gert de BorstPlasma fibrinogen level as predictor of hemorrhagic complications after catheter directed thrombolysis
Athanasios KatsargyrisPercutaneous thrombosuction for acute limb ischemia - equipment, technique and results
Martin BjörckEndovascular treatment of ALI is better than open surgery; results from a nationwide study with long-term follow-up
Kerstin StoklasaHow previous revascularizations affect the outcomes of acute limb ischemia – a consecutive cohort of 200 patients
TimeNameDescription

15.30-16.30

Mini-Symposium II: Vertebrobasilar strokes and carotid artery pseudoocclusion
Chair: Holger Poppert, NN

Afshin AssadianOpen surgical options to treat extracranial vertebral lesions
Athanasios GiannoukasAdvances in the treatment of posterior cerebral circulation symptomatic disease
Nabil ChakféTreatment of supra-aortic trunks occlusive disease
Klaus MathiasThe vertebral artery – a forgotten vessel?
Christos LiapisManagement of patients with internal carotid artery near-total occlusion.

Saturday, December 9

TimeNameDescription

09.00-10.20

VEN 1: Endovenous therapy or open surgery for primary varicosis - what is the evidence?
Chair: Ingo Flessenkämper, Richard Brandl

Achim MummeLong-term results of surgical and endovenous procedures for primary varicosis - an analysis of the past RCTs
Thomas PröbstleWhat can we learn from randomized trials comparing endovenous and open surgery for primary varicosis? – an overview
Claus-Georg SchmedtIs there any evidence that endovenous laser therapy or radiofrequency ablation or foam sclerotherapy is superior to each other?
Dimitrios TsantilasImpact of inguinal varicose veins recurrence and modern therapeutic strategies
Andreas FiebigKeynote lecture: New insights into the genetics of primary varicosis

10.20-11.15

VEN 2: Update on new endovenous technologies for primary varicosis
Chair: Achim Mumme, Klaus-Georg Schmedt

Thomas PröbstleThe European Sapheon™ Closure System Observational ProspectivE (eSCOPE) Study – clinical results and side effects of Venaseal
Tobias HirschNon-thermal / non-tumescent (NTNT) ablation of the truncal veins – indications and limitations
Richard BrandlThe introduction of glue in my venous armamentarium – 3-year results
Florian NetzerSteam Vein Sclerosis – an alternative to mini-phlebectomy?

11.45-12.55

VEN 3: Prevention and medical therapy of deep vein thrombosis (DVT)
Chair: Christine Espinola-Klein, Sebastian Schellong

Sebastian SchellongKeynote lecture: Oral anticoagulation and DVT: what is the evidence and is there a need to anticoagulate every lower leg DVT?
Thomas StadlbauerReduced-dosed Rivaroxaban in the long-term prevention of recurrent symptomatic DVT – the Einstein-Choice trial
Susanne SchreiberDVT as the first sign of an occult malignant disease- how often and what is the adequate diagnostic approach?
Thomas StadlbauerUpdate on the risk of DVT during air travel - does the economy class syndrome really exist?

12.55-13.55

VEN 4: Recanalization strategies in acute and chronic deep venous thrombosis
Chair: Ingo Flessenkämper, Tobias Hirsch

Sebastian SchellongWhat do we learn from the RCTs regarding venous recanalisation? How to design a trial which really moves the field forward?
Houman JalaieWhat does it need to perform endovenous recanalization in acute and chronic occlusions successfully - lessons learned
Stefan OckertAcute venous iliofemoral thrombosis: early surgical thrombectomy is effective and durable
Achim MummePhlegmasia coerulea dolens – diagnostics and management